Concepedia

Author

C. J. Edwards

University Hospital Southampton NHS Foundation TrustORCID

Also Known As

C EDWARDS, C Edwards, C J Edwards, C. Edwards, C. J. Edwards, C.J. Edwards, CJ Edwards, Cleo Edwards, Edwards, CJ, I. Sargeant

43

Publications

846

Citations

12

H-Index

0

Concepts

All Affiliations

University Hospital Southampton NHS Foundation TrustUniversity of Massachusetts Chan Medical SchoolUniversity of SheffieldBristol-Myers Squibb (Switzerland)Schön Klinik Hamburg Eilbek
CJ

About

C. J. Edwards is an author at University Hospital Southampton NHS Foundation Trust.

C. J. Edwards

×

6

Publications

385

Citations

6

H-Index

YearCitations

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients

C-S Yee, Vernon T. Farewell, David Isenberg,

Lara D. Veeken

2011

207

Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome

C. J. Edwards, T Y Lian, Humeira Badsha,

Lupus

2003

121

OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials

Dafna D. Gladman, Arthur Kavanaugh, Ade Adebajo,

Annals of the Rheumatic Diseases

2015

16

OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

C. Birbara, Francisco J. Blanco, Jeffrey Crowley,

Annals of the Rheumatic Diseases

2013

15

SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4)

A. Wells, C. J. Edwards, Ade Adebajo,

Annals of the Rheumatic Diseases

2015

14

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

Arthur Kavanaugh, Maurizio Cutolo, P. J. Mease,

Annals of the Rheumatic Diseases

2014

12

Page 1